Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.
Status:
Completed
Trial end date:
2018-11-05
Target enrollment:
Participant gender:
Summary
IBI306 is a fully human monoclonal antibody that binds proprotein convertase
substilisin/kexin type 9 (PCSK9), preventing its interaction with the low-density lipoprotein
cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density
lipoprotein cholesterol（LDL-C）uptake. This is a randomized, double-blind,
placebo-controlled,single ascending dose study to evaluate the safety, tolerability,
pharmacokinetics/pharmacodynamics and immunogenicity of IBI306 in healthy adults.